Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) changed -3.11% to recent value of $101.64. The stock transacted 143637 shares during most recent day however it has an average volume of 178.86K shares. It spotted trading -67.26% off 52-week high price. On the other end, the stock has been noted 13.15% away from the low price over the last 52-weeks.
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) declared that Jim Daly has been appointed to the Company’s Board of Directors, as a Class I director, effective as of June 27, 2019.
“We are extremely pleased to have an executive with Jim’s leadership and commercial experience join our Board of Directors,” stated Paul Friedman, M.D., Chief Executive Officer of Madrigal. “His expertise in commercial development, product launch, sales and marketing, and business development will be especially valuable as we advance resmetirom through Phase 3 clinical studies and prepare for commercialization.”
Mr. Daly said “I am excited to join the Madrigal Board”. “I believe NASH and NAFLD will be large and attractive market opportunities, and resmetirom is likely to be a best-in-class therapy with the potential to benefit a substantial number of patients.”
Mr. Daly has over 30 years of experience leading U.S. and global businesses in the biopharmaceutical industry and currently serves as a Director of Acadia Pharmaceuticals, argenx SE, Bellicum Pharmaceuticals, Halozyme Therapeutics, and Chimerix, Inc. Most recently, Mr. Daly served as Executive Vice President and Chief Commercial Officer at Incyte Corporation from 2012 to 2015. Previously, Mr. Daly worked for Amgen, Inc. and held various leadership positions over a 10-year period, including his last role as Senior Vice President, North America Commercial Operations, Global Marketing and Commercial Development. Earlier in his career, he spent over 16 years with Glaxo Wellcome/GlaxoSmithKline (GSK) where he held roles of increasing responsibility, including his last role as Senior Vice President, General Manager of the Respiratory and Anti-Infective Business Unit. He earned a B.S. in Pharmacy and an M.B.A. from the University at Buffalo, The State University of New York.
MDGL . Its earnings per share (EPS) expected to touch remained 12.80% for this year while earning per share for the next 5-years is expected to reach at 0.00%.
The company has 14.78M of outstanding shares and 13.81M shares were floated in the market. According to the most recent quarter its current ratio was 45.8 that represents company’s ability to meet its current financial obligations. The price moved ahead of 0.70% from the mean of 20 days, 0.14% from mean of 50 days SMA and performed -23.48% from mean of 200 days price. Company’s performance for the week was 1.18%, 5.37% for month and YTD performance remained -9.83%.
Daniel Johnson studied a business degree majoring in finance and security analysis. He has a deep understanding of both technical and fundamental forms of analysis, he deeply believes that it makes a lot more sense for average investors to understand fundamental analysis, which he believes anyone can learn. Daniel has over 10 years of experience as a professional journalist, writer and an editor. He holds a bachelor’s degree in International Business from University of Melbourne. He writes articles about hot stocks, dividend growth investing, options trading, investment decisions, stock selection, portfolio management, and passive income generation. Daniel also reports on Finance category.
Email Contact: [email protected]
Address: 4487 Roger Street, Nanaimo, British Columbia
Zip Code: V9R 5H9
Phone Number: 250-760-7308